Erythromycin A oxime (CAS 111321-02-9)

Erythromycin A oxime, cataloged under CAS number 111321-02-9, is a derivative of the parent compound erythromycin A, characterized by the substitution of its ketone group with an oxime group. This chemical modification significantly influences the molecule′s properties, including its stability and interaction with biological targets. The oxime group in erythromycin A oxime is particularly interesting for its potential to alter the molecule′s binding dynamics with bacterial ribosomes, which are critical for protein synthesis in bacterial cells. In research, erythromycin A oxime has been employed as a tool to study the effects of structural changes on the activity of macrolide antibiotics against bacterial populations. The introduction of the oxime group can potentially affect how the molecule interacts with the peptidyl transferase center of the ribosome, thus providing insights into the mechanism of action at a molecular level. Researchers utilize this compound to explore variations in antibiotic interaction that could lead to differences in efficacy and bacterial resistance profiles. Studies involving erythromycin A oxime are crucial for understanding the complex relationships between antibiotic structure and function, particularly in the context of designing molecules with improved properties or reduced resistance potential. This research is fundamental in advancing our knowledge of antibiotic action and could inform future developments in antibiotic design.